3,151 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Blackhawk Capital Partners LLC.

Blackhawk Capital Partners LLC. acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,151 shares of the company’s stock, valued at approximately $245,000.

Other institutional investors and hedge funds have also modified their holdings of the company. State Board of Administration of Florida Retirement System purchased a new position in shares of AstraZeneca in the first quarter valued at approximately $1,524,000. CANADA LIFE ASSURANCE Co grew its holdings in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after buying an additional 146 shares in the last quarter. Advisors Asset Management Inc. grew its holdings in shares of AstraZeneca by 6.8% during the first quarter. Advisors Asset Management Inc. now owns 60,455 shares of the company’s stock worth $4,096,000 after buying an additional 3,831 shares in the last quarter. Capital International Inc. CA lifted its stake in shares of AstraZeneca by 17.5% in the first quarter. Capital International Inc. CA now owns 238,030 shares of the company’s stock worth $16,127,000 after buying an additional 35,458 shares in the last quarter. Finally, Capital International Ltd. CA boosted its position in AstraZeneca by 1.8% during the first quarter. Capital International Ltd. CA now owns 43,620 shares of the company’s stock worth $2,955,000 after acquiring an additional 759 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on AZN shares. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday. Finally, Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $63.20 on Thursday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The stock has a 50-day moving average of $73.99 and a two-hundred day moving average of $77.95. The company has a market cap of $195.96 billion, a P/E ratio of 30.24, a P/E/G ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.87 earnings per share. As a group, analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.